The global healthcare company was named an honoree in the Digital Health category of the 2025 CES Innovations Awards program, an annual competition by the U.S. Consumer Technology Association that highlights outstanding design and engineering in consumer technology products worldwide.
Earlier this month, the device equipped with advanced technology was presented at the Consumer Electronics Show 2025, held from Jan. 5-10 in Las Vegas, Nevada.
Built on the FreeStyle Libre continuous glucose monitoring technology—now used by more than 6 million people with diabetes globally—Lingo tracks users’ glucose levels continuously. The system is similar to Abbott’s CGM system, FreeStyle Libre 3, which has previously won several CES Innovation Awards.
“Glucose is a powerful signal of your body’s unique response to food and lifestyle,” said Olivier Ropars, divisional vice president of Abbott’s Lingo business. “Abbott’s Lingo tracks your glucose 24/7, translating the data into insights and bridging the gap between traditional healthcare and preventative measures. Lingo empowers individuals to build new healthy habits and take control of their health and wellness.”
At CES 2025, Abbott noted that Lingo is designed for consumers aged 18 and older who are not on insulin but are looking to improve their overall health and wellness. The system includes a biosensor worn on the back of the arm for up to 14 days that continuously streams glucose data to the Lingo app on a smartphone.
Lingo worn by a man translates his body reaction to jogging into personal insights at the Consumer Electronics Show 2025 in Las Vegas. Photo courtesy of Abbott |
The device interprets the body’s responses to food, exercise, and daily stressors, providing personalized insights about metabolic trends to help users make informed health decisions.
The Lingo app displays a glucose graph, a Lingo count indicating glucose spikes, food and activity logs, and tailored recommendations based on logged food times and accumulated data.
Additionally, the system offers challenges to encourage new habits, awarding badges for completing tasks and establishing healthy routines. Published research suggests that managing glucose spikes and overall glucose levels can benefit people without diabetes by promoting proactive health measures, weight management, improved sleep, and better mood.
Lingo is part of Abbott’s broader range of healthcare products, which include nutritionals, medicines, diagnostics, and medical devices aimed at supporting health throughout all stages of life.
 |
People visit Abbott’s booth at the CES 2025. Photo courtesy of Abbott |
Another notable Abbott product, the FreeStyle Libre, has significantly changed diabetes management for millions worldwide. In 2022, FreeStyle Libre was recognized as the “best of the best” at the Prix Galien Golden Jubilee Awards, highlighting its impact on approximately 4.5 million people with diabetes globally.
The FreeStyle Libre technology was introduced in Vietnam in 2021, reflecting Abbott’s commitment to bringing diverse healthcare innovations to the country, where it has maintained a presence for 30 years.
Abbott has also introduced other healthcare solutions in Vietnam, such as the Amplatzer Piccolo Occluder for treating patent ductus arteriosus in premature infants and a Clinical Decision Support system that uses AI to enhance clinical management.
Additionally, Abbott and the Abbott Fund have provided significant support in Vietnam, offering over VND280 billion (US$12 million) in grants and donations aimed at improving nutrition, training healthcare staff, strengthening health systems, assisting pandemic frontline professionals, and expanding community education.
These efforts and products contribute to advancing healthcare and promoting strength and health throughout the nation.
Comments are closed.